Immortal Dragons, a $40 million longevity fund, has made a significant investment in Frontier Bio, a company leading the charge in biofabrication technology. Utilizing advancements in 3D biofabrication, stem cells, organ-on-a-chip, and perfusion bioreactor technologies, Frontier Bio is addressing substantial unmet medical needs in a market exceeding $12 billion annually, where existing synthetic solutions face failure rates as high as 65%.

Frontier Bio has developed a groundbreaking technology that creates functional blood vessels, which exhibit exceptional performance metrics, including no thrombosis, significant cell infiltration, proper endothelium formation, and seamless integration with adjacent tissue. Their in vitro testing tissues feature microfluidic organ-on-a-chip platforms, creating human blood-brain barrier models and a 3D bioprinted mini-lung, both aimed at expediting pre-clinical trials and providing more precise experimental outcomes than traditional animal testing.

The innovative tissue-engineered blood vessels from Frontier Bio mitigate the thrombosis risks associated with current synthetic grafts. In extensive studies conducted on large animals, the company’s vascular grafts showcased outstanding results in the carotid artery, remaining patent with integration into surrounding tissue and, importantly, exhibiting no thrombosis or infection after 14 days post-implantation.

This advancement marks a significant leap over conventional synthetic vascular grafts, which typically experience thrombosis within similar timeframes. The grafts from Frontier Bio are seeded with stem cells, allowing for notable cell invasion throughout the graft and proper endothelium formation.

The technology offers several benefits, including off-the-shelf availability, compatibility with small diameter vessels, cellularization at the time of implantation, and the ability to create complex vessel geometries. These characteristics position Frontier Bio's grafts as superior alternatives to both autologous vessels (which are limited in availability) and current synthetic options (which perform poorly, particularly in small diameters under 5mm).

"Refreshing to meet investors fluent in the field, technology, and related domains. Immortal Dragons acted on insight, not hype," remarked Eric Bennett, CEO of Frontier Bio.

This investment aligns strategically with the goal of addressing organ failure, the leading cause of mortality for individuals over 65. By developing scalable 3D biofabrication technologies for creating functional organs and tissues, Frontier Bio targets a $150 billion organ transplant market while reinforcing one of Immortal Dragons' central theses: that aging-related deaths can be mitigated through replacement technologies.

Many patients currently endure extensive organ transplant waiting lists, with numerous individuals succumbing daily due to severe shortages. Frontier Bio’s platform could revolutionize this situation by enabling on-demand organ manufacturing using patients' own cells, thus minimizing rejection risks and wait times. As Boyang Wang, founder of Immortal Dragons, stated: "3D Biofabrication represents a critical piece of replacement technologies, having the ability to manufacture specific organs and tissues on-demand provides the foundational infrastructure that makes biological part replacement possible."

Looking ahead, Frontier Bio's 3D biofabrication capabilities create strong synergies within Immortal Dragons' portfolio. Their organ printing technology supports whole-body replacement initiatives, providing the necessary infrastructure to produce replacement organs at scale. Additionally, the bioprinting platform's tissue engineering capabilities contribute to artificial womb development, generating complex vascular networks and specialized tissues essential for external gestation systems. The synergy of 3D biofabrication technology with other replacement technologies fosters a holistic ecosystem of mutually reinforcing longevity solutions.

This comprehensive vision resonates with leading researchers in the field. Brian Kennedy, a distinguished professor and notable longevity leader at the National University of Singapore, emphasized: "Immortal Dragons is making thoughtful, mission-driven investments in longevity by supporting high-impact science with long-term potential."